Risks and mitigation strategies to prevent etoposide infusion‐related reactions in children
Etoposide is an antineoplastic agent widely used for treatment of many pediatric cancers. Etoposide has been associated with infusion‐related reactions. In this brief report, we compare etoposide infusion‐related reactions that occurred over a 10‐year period at two freestanding pediatric hospitals....
Gespeichert in:
| Veröffentlicht in: | Pharmacotherapy 2021-08, Vol.41 (8), p.700-706 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 706 |
|---|---|
| container_issue | 8 |
| container_start_page | 700 |
| container_title | Pharmacotherapy |
| container_volume | 41 |
| creator | Tillman, Emma M. Suppes, Sarah L. Miles, Nicholas Duty, Ashley M. Kelley, Kelsey L. Goldman, Jennifer L. |
| description | Etoposide is an antineoplastic agent widely used for treatment of many pediatric cancers. Etoposide has been associated with infusion‐related reactions. In this brief report, we compare etoposide infusion‐related reactions that occurred over a 10‐year period at two freestanding pediatric hospitals. Infusion reactions occurred in 1% of patients at two hospitals across the study period. Rates of 4.8%, 3.4%, and 7.9% were observed at Children's Mercy Hospital during 2018, 2019, and 2020, respectively, after the implementation of in‐line filters during etoposide infusions in late 2017. Of the 32 patients who experienced adverse reactions, 41% were rechallenged after the reaction and all were able to tolerate at least one future dose with either pre‐treatment or extending infusion duration. This work highlights the importance of a multicenter approach to investigating adverse drug reactions (ADRs) as variation in practice can provide key information about ADRs and potential risk factors. |
| doi_str_mv | 10.1002/phar.2603 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8617599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2560588366</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4433-3b7182f030fa0954fed3601203a5892efa6767a4739aa226fa65b6800b3928d33</originalsourceid><addsrcrecordid>eNp1kctKAzEUhoMoWi8LX0ACrlyMniQzSWYjlOINBKXoUkI6k2mj08mYTCvd-Qg-o09ialV04SqE8-XLz_kR2idwTADoSTvR_phyYGuoR6TIkpyQdB31gAqRAIDcQtshPEaU8JRuoi2WEpoLyHroYWjDU8C6KfHUdnasO-saHDqvOzO2JuDO4dabuWk6bDrXumBLg21TzUIE31_fvKkjWmJvdLF8G-IQFxNbl940u2ij0nUwe1_nDro_P7sbXCbXNxdXg_51UqQpYwkbCSJpBQwqDXmWVqZkHAgFpjOZU1NpLrjQqWC51pTyeM9GXAKMWE5lydgOOl1529loasoipvW6Vq23U-0Xymmr_k4aO1FjN1eSE5HleRQcfgm8e56Z0KlHN_NNzKxoxiGTknEeqaMVVXgXgjfVzw8E1LIJtWxCLZuI7MHvSD_k9-ojcLICXmxtFv-b1O1lf_ip_ABwE5W3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2560588366</pqid></control><display><type>article</type><title>Risks and mitigation strategies to prevent etoposide infusion‐related reactions in children</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Tillman, Emma M. ; Suppes, Sarah L. ; Miles, Nicholas ; Duty, Ashley M. ; Kelley, Kelsey L. ; Goldman, Jennifer L.</creator><creatorcontrib>Tillman, Emma M. ; Suppes, Sarah L. ; Miles, Nicholas ; Duty, Ashley M. ; Kelley, Kelsey L. ; Goldman, Jennifer L.</creatorcontrib><description>Etoposide is an antineoplastic agent widely used for treatment of many pediatric cancers. Etoposide has been associated with infusion‐related reactions. In this brief report, we compare etoposide infusion‐related reactions that occurred over a 10‐year period at two freestanding pediatric hospitals. Infusion reactions occurred in 1% of patients at two hospitals across the study period. Rates of 4.8%, 3.4%, and 7.9% were observed at Children's Mercy Hospital during 2018, 2019, and 2020, respectively, after the implementation of in‐line filters during etoposide infusions in late 2017. Of the 32 patients who experienced adverse reactions, 41% were rechallenged after the reaction and all were able to tolerate at least one future dose with either pre‐treatment or extending infusion duration. This work highlights the importance of a multicenter approach to investigating adverse drug reactions (ADRs) as variation in practice can provide key information about ADRs and potential risk factors.</description><identifier>ISSN: 0277-0008</identifier><identifier>EISSN: 1875-9114</identifier><identifier>DOI: 10.1002/phar.2603</identifier><identifier>PMID: 34129705</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Child ; Children ; drug hypersensitivity ; Drug-Related Side Effects and Adverse Reactions - prevention & control ; drug‐related side effects and adverse reactions ; Etoposide ; Etoposide - administration & dosage ; Etoposide - adverse effects ; Hospitals ; Humans ; Infusions, Intravenous - adverse effects ; Neoplasms - drug therapy ; Patients ; Pediatrics ; Risk Factors</subject><ispartof>Pharmacotherapy, 2021-08, Vol.41 (8), p.700-706</ispartof><rights>2021 Pharmacotherapy Publications, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4433-3b7182f030fa0954fed3601203a5892efa6767a4739aa226fa65b6800b3928d33</citedby><cites>FETCH-LOGICAL-c4433-3b7182f030fa0954fed3601203a5892efa6767a4739aa226fa65b6800b3928d33</cites><orcidid>0000-0001-8019-9811</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fphar.2603$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fphar.2603$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34129705$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tillman, Emma M.</creatorcontrib><creatorcontrib>Suppes, Sarah L.</creatorcontrib><creatorcontrib>Miles, Nicholas</creatorcontrib><creatorcontrib>Duty, Ashley M.</creatorcontrib><creatorcontrib>Kelley, Kelsey L.</creatorcontrib><creatorcontrib>Goldman, Jennifer L.</creatorcontrib><title>Risks and mitigation strategies to prevent etoposide infusion‐related reactions in children</title><title>Pharmacotherapy</title><addtitle>Pharmacotherapy</addtitle><description>Etoposide is an antineoplastic agent widely used for treatment of many pediatric cancers. Etoposide has been associated with infusion‐related reactions. In this brief report, we compare etoposide infusion‐related reactions that occurred over a 10‐year period at two freestanding pediatric hospitals. Infusion reactions occurred in 1% of patients at two hospitals across the study period. Rates of 4.8%, 3.4%, and 7.9% were observed at Children's Mercy Hospital during 2018, 2019, and 2020, respectively, after the implementation of in‐line filters during etoposide infusions in late 2017. Of the 32 patients who experienced adverse reactions, 41% were rechallenged after the reaction and all were able to tolerate at least one future dose with either pre‐treatment or extending infusion duration. This work highlights the importance of a multicenter approach to investigating adverse drug reactions (ADRs) as variation in practice can provide key information about ADRs and potential risk factors.</description><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Child</subject><subject>Children</subject><subject>drug hypersensitivity</subject><subject>Drug-Related Side Effects and Adverse Reactions - prevention & control</subject><subject>drug‐related side effects and adverse reactions</subject><subject>Etoposide</subject><subject>Etoposide - administration & dosage</subject><subject>Etoposide - adverse effects</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Infusions, Intravenous - adverse effects</subject><subject>Neoplasms - drug therapy</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Risk Factors</subject><issn>0277-0008</issn><issn>1875-9114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctKAzEUhoMoWi8LX0ACrlyMniQzSWYjlOINBKXoUkI6k2mj08mYTCvd-Qg-o09ialV04SqE8-XLz_kR2idwTADoSTvR_phyYGuoR6TIkpyQdB31gAqRAIDcQtshPEaU8JRuoi2WEpoLyHroYWjDU8C6KfHUdnasO-saHDqvOzO2JuDO4dabuWk6bDrXumBLg21TzUIE31_fvKkjWmJvdLF8G-IQFxNbl940u2ij0nUwe1_nDro_P7sbXCbXNxdXg_51UqQpYwkbCSJpBQwqDXmWVqZkHAgFpjOZU1NpLrjQqWC51pTyeM9GXAKMWE5lydgOOl1529loasoipvW6Vq23U-0Xymmr_k4aO1FjN1eSE5HleRQcfgm8e56Z0KlHN_NNzKxoxiGTknEeqaMVVXgXgjfVzw8E1LIJtWxCLZuI7MHvSD_k9-ojcLICXmxtFv-b1O1lf_ip_ABwE5W3</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Tillman, Emma M.</creator><creator>Suppes, Sarah L.</creator><creator>Miles, Nicholas</creator><creator>Duty, Ashley M.</creator><creator>Kelley, Kelsey L.</creator><creator>Goldman, Jennifer L.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8019-9811</orcidid></search><sort><creationdate>202108</creationdate><title>Risks and mitigation strategies to prevent etoposide infusion‐related reactions in children</title><author>Tillman, Emma M. ; Suppes, Sarah L. ; Miles, Nicholas ; Duty, Ashley M. ; Kelley, Kelsey L. ; Goldman, Jennifer L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4433-3b7182f030fa0954fed3601203a5892efa6767a4739aa226fa65b6800b3928d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Child</topic><topic>Children</topic><topic>drug hypersensitivity</topic><topic>Drug-Related Side Effects and Adverse Reactions - prevention & control</topic><topic>drug‐related side effects and adverse reactions</topic><topic>Etoposide</topic><topic>Etoposide - administration & dosage</topic><topic>Etoposide - adverse effects</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Infusions, Intravenous - adverse effects</topic><topic>Neoplasms - drug therapy</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tillman, Emma M.</creatorcontrib><creatorcontrib>Suppes, Sarah L.</creatorcontrib><creatorcontrib>Miles, Nicholas</creatorcontrib><creatorcontrib>Duty, Ashley M.</creatorcontrib><creatorcontrib>Kelley, Kelsey L.</creatorcontrib><creatorcontrib>Goldman, Jennifer L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tillman, Emma M.</au><au>Suppes, Sarah L.</au><au>Miles, Nicholas</au><au>Duty, Ashley M.</au><au>Kelley, Kelsey L.</au><au>Goldman, Jennifer L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risks and mitigation strategies to prevent etoposide infusion‐related reactions in children</atitle><jtitle>Pharmacotherapy</jtitle><addtitle>Pharmacotherapy</addtitle><date>2021-08</date><risdate>2021</risdate><volume>41</volume><issue>8</issue><spage>700</spage><epage>706</epage><pages>700-706</pages><issn>0277-0008</issn><eissn>1875-9114</eissn><abstract>Etoposide is an antineoplastic agent widely used for treatment of many pediatric cancers. Etoposide has been associated with infusion‐related reactions. In this brief report, we compare etoposide infusion‐related reactions that occurred over a 10‐year period at two freestanding pediatric hospitals. Infusion reactions occurred in 1% of patients at two hospitals across the study period. Rates of 4.8%, 3.4%, and 7.9% were observed at Children's Mercy Hospital during 2018, 2019, and 2020, respectively, after the implementation of in‐line filters during etoposide infusions in late 2017. Of the 32 patients who experienced adverse reactions, 41% were rechallenged after the reaction and all were able to tolerate at least one future dose with either pre‐treatment or extending infusion duration. This work highlights the importance of a multicenter approach to investigating adverse drug reactions (ADRs) as variation in practice can provide key information about ADRs and potential risk factors.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34129705</pmid><doi>10.1002/phar.2603</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-8019-9811</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-0008 |
| ispartof | Pharmacotherapy, 2021-08, Vol.41 (8), p.700-706 |
| issn | 0277-0008 1875-9114 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8617599 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Child Children drug hypersensitivity Drug-Related Side Effects and Adverse Reactions - prevention & control drug‐related side effects and adverse reactions Etoposide Etoposide - administration & dosage Etoposide - adverse effects Hospitals Humans Infusions, Intravenous - adverse effects Neoplasms - drug therapy Patients Pediatrics Risk Factors |
| title | Risks and mitigation strategies to prevent etoposide infusion‐related reactions in children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T20%3A49%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risks%20and%20mitigation%20strategies%20to%20prevent%20etoposide%20infusion%E2%80%90related%20reactions%20in%20children&rft.jtitle=Pharmacotherapy&rft.au=Tillman,%20Emma%20M.&rft.date=2021-08&rft.volume=41&rft.issue=8&rft.spage=700&rft.epage=706&rft.pages=700-706&rft.issn=0277-0008&rft.eissn=1875-9114&rft_id=info:doi/10.1002/phar.2603&rft_dat=%3Cproquest_pubme%3E2560588366%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2560588366&rft_id=info:pmid/34129705&rfr_iscdi=true |